Literature DB >> 9464449

Altered expression of cyclic nucleotide phosphodiesterase isozymes during culture of aortic endothelial cells.

T Ashikaga1, S J Strada, W J Thompson.   

Abstract

Primary cultures of bovine aortic endothelial cells (BAEC) express cyclic nucleotide phosphodiesterase (CN PDE) isozymes of the PDE2, PDE4 and PDE5 gene families. We report here that the isozyme profiles of CN PDE and the amounts of each vary with the passage number of BAEC cultures. Characterization by anion-exchange chromatography and pharmacological criteria were used to study CN PDE in early (4-6), intermediate (6-10), and late (> 17) passages of purified BAEC. PDE2 and a minor fraction of PDE5 accounted for cyclic GMP hydrolysis in early passages, but both isozymes were lost with cell passage. Cyclic AMP was hydrolyzed by both PDE2 and PDE4 isozymes in early passage endothelial cells, but PDE4 was increased dramatically in higher passage cells. Also appearing in the higher passage cells were prominent PDE1 and minor PDE3 activities. The ratios of cytosolic to particulate activities were similar at all passages. BAEC PDE isoforms in intact cells assessed by [3H]-adenine prelabeling showed that atriopeptin II decreased isoproterenol-induced cyclic AMP accumulation in early but not later passage cells, consistent with the loss of PDE2 expression. Enhancement of isoproterenol-induced cyclic AMP accumulation by rolipram, a PDE4 inhibitor, was also greatly diminished during culture passages. Changes in CN PDE isoform expression and consequent cyclic AMP turnover validate the importance of considering cell passage number when cultures of BAEC are used to study the regulation of endothelial cell cyclic nucleotide metabolism and processes mediated by cyclic nucleotides in this model system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9464449     DOI: 10.1016/s0006-2952(97)00287-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

Review 1.  PDE1 isozymes, key regulators of pathological vascular remodeling.

Authors:  Stefan Chan; Chen Yan
Journal:  Curr Opin Pharmacol       Date:  2011-09-29       Impact factor: 5.547

2.  Phosphodiesterase-5A (PDE5A) is localized to the endothelial caveolae and modulates NOS3 activity.

Authors:  Milena A Gebska; Blake K Stevenson; Anna R Hemnes; Trinity J Bivalacqua; Azeb Haile; Geoffrey G Hesketh; Christopher I Murray; Ari L Zaiman; Marc K Halushka; Nispa Krongkaew; Travis D Strong; Carol A Cooke; Hazim El-Haddad; Rubin M Tuder; Dan E Berkowitz; Hunter C Champion
Journal:  Cardiovasc Res       Date:  2011-03-18       Impact factor: 10.787

Review 3.  Regulation of endothelial barrier function by cyclic nucleotides: the role of phosphodiesterases.

Authors:  James Surapisitchat; Joseph A Beavo
Journal:  Handb Exp Pharmacol       Date:  2011

4.  PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER.

Authors:  Amanda G Vang; Shlomo Z Ben-Sasson; Hongli Dong; Barbara Kream; Michael P DeNinno; Michelle M Claffey; William Housley; Robert B Clark; Paul M Epstein; Stefan Brocke
Journal:  PLoS One       Date:  2010-08-09       Impact factor: 3.240

Review 5.  Cyclic nucleotide compartmentalization: contributions of phosphodiesterases and ATP-binding cassette transporters.

Authors:  Satish Cheepala; Jean-Sebastien Hulot; Jessica A Morgan; Yassine Sassi; Weiqiang Zhang; Anjaparavanda P Naren; John D Schuetz
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-10-16       Impact factor: 13.820

6.  Heparan sulphate glycosaminoglycans derived from endothelial cells and smooth muscle cells differentially modulate fibroblast growth factor-2 biological activity through fibroblast growth factor receptor-1.

Authors:  David Berry; Zachary Shriver; Barbara Natke; Chi-Pong Kwan; Ganesh Venkataraman; Ram Sasisekharan
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

Review 7.  The Role of PDE8 in T Cell Recruitment and Function in Inflammation.

Authors:  Paul M Epstein; Chaitali Basole; Stefan Brocke
Journal:  Front Cell Dev Biol       Date:  2021-04-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.